Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
BIOCANCER Clinical Research S.A. Junho - 2006 COMPANY We are a Site Management Organization (SMO) focused in running Clinical Trials. We are able to assist pharmaceutical, biotechnology, medical device and drug development services companies to have access to Brazil’s large population of patients through its already consolidated network of hospitals (either private or public), laboratories, specialized personnel and others. 2 COMPANY From the discovery-stage to late-phase clinical trials, BioCancer's wide range of integrated services is designed to help companies reduce costs, minimize risks and accelerate time to market while optimizing the overall quality and experience of the new drug development process. 3 DIFFERENTIATION Our aim is to provide the highest quality, most rapid and cost effective process for the completion of clinical studies, allowing the sponsor to reduce time taken from the start of Phase I studies until the completion of all Phase III studies, with the state-of-the-art quality. 4 SERVICES The company's service offerings include: site definition, patient and investigator recruitment; clinical trial planning; medical writing, protocol design and review; database design; data entry and verification; biostatistician analysis and the generation of clinical trial reports. 5 INFRA STRUCTURE We manage: 7 hospitals, 3 private practice clinics, 1 fully equipped lab entirely devoted to research, a tissue bank already approved and collecting samples, and other facilities. We have access to more than 10.000 patients/month and we are able to support virtually any technological requirement that might be necessary in the R & D process from phase I to IV clinical trials. 6 OUR TEAM We are scientists, physicians and technical professionals with international clinical trial experience providing expert consulting services to government, Pharmaceutical and Biotechnology Companies. We are highly qualified in regulatory affairs, clinical and preclinical studies management, medical writing, quality assurance, data management, data analysis, scientific report generation, information research, technology assessment, and strategic planning. 7 BIOCANCER´S: LEADERSHIP TEAM DR. ALBERTO WAINSTEIN, MD, PhD. Chief Medical Officer Dr. Wainstein has 10 years of clinical research experience. He has served as the principal investigator or sub-investigator for many studies involving pharmacokinetics, pharmacodynamics, drug-drug interaction and mechanism of action. He is a general Surgeon in charge at the Minas Gerais State Hospital Foundation, a general Surgeon at the Civil Police Hospital; General Surgeon on duty at Hospital Mater Dei; Preceptor of the residence program in Surgery at Federal University Of Minas Gerais, Hospital das Clínicas; Post Doctor fellow at Karmanos Cancer Institute; Post-Doctor Fellowship in Tumor Immunotherapy - Albert Einstein Cancer Center – New York – USA; Post-Doctor Fellowship in Cancer Biological Karmanos Cancer Institute – Michigan –USA; Therapy – Phd at Ludwig Institute of Cancer Research - Hospital do Cancer, Master in Medicine BIOCANCER´S LEADERSHIP TEAM DR. CARLOS GUIMARÃES, MBA Chief Executive Officer Mr. Guimaraes is graduated in Business Administration at Federal University of Minas Gerais –Brazil (UFMG), pos graduated in Finance at Federal University of Minas Gerais –Brazil (UFMG), and got his MBA Executive International degree at FDC/Sauder Business School (Vancouver, Canada). Former director of successful Brazilian biotech company, he was responsible for an extraordinary national and international expansion, followed by a merge process that he also coordinated. He has a broad international experience, a strong ability to lead teams, and an exceptional performance in the commercial area. Over the last 10 years he has been running different business and since May 2006, was in charge of lead Biocancer to a distinguish position in clinical trials in the world. BIOCANCER´S: LEADERSHIP TEAM DRA. ANA PAULA DRUMMOND, MD, PharmD Chief Scientific Officer Bachelor’s degree in Pharmacy from the Federal University of Minas Gerais (UFMG) (Belo Horizonte, Brazil), Specialization in Industrial Phamacology at Federal University of Minas Gerais (UFMG); MSc in Physiology and Pharmacology from the Federal University of Minas Gerais (UFMG); Ph.D. inumor Immunology from the Federal University of Minas Gerais (UFMG); Fellowship in Cell Biology at Karmanos Cancer Center (MI, USA); Fellowship in Cellular Immunobiology (Clinical Trials) at Memorial Sloan-Ketering Cancer Cener (NY, USA); Post-doctorate in Cancer Vaccines from the Federal University of Minas Gerais (UFMG) ; PROTOCOL’S PORTFOLIO Some of our studies, among others (not listed): • A Phase I study, to evaluate the efficacy and safety of a vaccine based on dendritic cells pulsed with specific peptides in patients with prostate carcinoma who are hormone resistant. (Biocancer own study) • A Phase I study, to evaluate the efficacy and safety of a vaccine based on dendritic cells pulsed with apoptotic bodies and lysates of autologous tumor in patients with metastatic melanoma. (Biocancer own study) • A Phase I study, to evaluate the efficacy and safety of an intralinphonodal vaccine based on multi-peptides associated to GM-CSF in patients with melanoma and high risk of 11 recurrence. (Biocancer own study) PROTOCOL’S PORTFOLIO • A Phase III, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of XXXX in patients with locally advanced or metastatic renal cell carcinoma who have progressed following cytokine-based first line treatment. • A phase III, randomized, double-blind, placebo-controlled to evaluate the efficacy of XXXX in patients with clear cell renal cancer with high risk of recurrence. 12 PROTOCOL’S PORTFOLIO • • • A Phase III, randomized, double-blind, placebo-controlled, multi-center, multi-national study to evaluate the efficacy and safety of XXXX in patients with solid tumors treated with platinum derivates. A Phase III, randomized, double-blind, placebo control, multicenter, multi-national to evaluate the efficacy and safety of XXXX in patients with solid tumors or hematological tumors non-mileoides treated without platinum derivates. A Phase III, randomized, double-blind, placebo-controlled, multi-center, multi-national to evaluate the efficacy and safety of XXXX in anemic patients with non-Hodgkin lymphoma, CLL or multiple mieloma treated with anticancer therapy. 13 PROTOCOL’S PORTFOLIO • A Randomized, Placebo Controlled, Multi-Center Phase 3 Trial of XXX on prolonging bone metastasesfree survival in men Hormone-Refractory Prostate Cancer. • A Phase 1 single centre, cross-over, single-blind study to evaluate the safety, tolerability and pharmacokinetics of different formulations of XXX in post menopausal women. • A Phase 1 single centre, cross-over, single-blind study to evaluate the safety, tolerability and pharmacokinetics of different formulations of YYY in post menopausal women. 14 PROTOCOL’S PORTFOLIO • • • A Phase 1 single centre study to evaluate the safety and tolerability of XXX in sinusitis patients. A Phase III study of XXX plus XXX versus XXX plus XXX in patients with unresectable, locally recurrent or metastatic breast cancer after prior anthracycline-based adjuvant chemotherapy Others. 15